NCT05357976

Brief Summary

Obesity has become one of the world's leading health problems. It is known that obesity causes many diseases and negatively affects the quality of life. For this reason, many conditions that are thought to be effective in obesity and concern the quality of life of patients have been scientifically researched and continue to be investigated. One of them is postoperative pain. Although there are studies stating that there is no relationship between body mass index (BMI) and postoperative pain, when the literature data is examined, it is thought that obesity is a risk factor for postoperative pain and changes pain sensitivity and analgesic needs of patients. There are also studies in the literature stating that the level of postoperative pain increases in parallel with each unit increase in BMI. After thoracic surgery, many analgesic methods have been suggested, including thoracic epidural analgesia (TEA), thoracic paravertebral block (TPVB), intercostal nerve blocks (ICSB), erector spina plane block (ESPB), serratus anterior plane block (SAPB). This study will compare the effects of BMI on postoperative pain in patients undergoing TPVB for postoperative analgesia and thoracoscopic surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
75

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2022

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 25, 2022

Completed
Same day until next milestone

Study Start

First participant enrolled

April 25, 2022

Completed
8 days until next milestone

First Posted

Study publicly available on registry

May 3, 2022

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2023

Completed
12 days until next milestone

Study Completion

Last participant's last visit for all outcomes

May 13, 2023

Completed
Last Updated

May 16, 2023

Status Verified

May 1, 2023

Enrollment Period

1 year

First QC Date

April 25, 2022

Last Update Submit

May 13, 2023

Conditions

Outcome Measures

Primary Outcomes (6)

  • Pain Scores

    Pain will be assessed at the first-hour rest and while coughing using the visual analog scale on a scale from 0 (no pain) to 10 (worst pain). Pain assessment will be done at the 1st, 2nd, 4th, 12th, 24th, and 48th hours after surgery.

    1st hour after surgery.

  • Pain Scores

    Pain will be assessed at the 2nd-hour rest and while coughing using the visual analog scale on a scale from 0 (no pain) to 10 (worst pain).

    2nd-hour after surgery.

  • Pain Scores

    Pain will be assessed at the 4th-hour rest and while coughing using the visual analog scale on a scale from 0 (no pain) to 10 (worst pain).

    4th-hour after surgery.

  • Pain Scores

    Pain will be assessed at the 12th-hour rest and while coughing using the visual analog scale on a scale from 0 (no pain) to 10 (worst pain).

    12th-hour after surgery.

  • Pain Scores

    Pain will be assessed at the 24th-hour rest and while coughing using the visual analog scale on a scale from 0 (no pain) to 10 (worst pain).

    24th-hour after surgery.

  • Pain Scores

    Pain will be assessed at the 48th-hour rest and while coughing using the visual analog scale on a scale from 0 (no pain) to 10 (worst pain).

    48th-hour after surgery.

Secondary Outcomes (1)

  • Morphine Consumption

    24 hours after surgery

Study Arms (3)

Patients with a BMI of 18-24.9 kg/m2

ACTIVE COMPARATOR

The needle will be advanced to the paravertebral area with an ultrasound-guided in-plane technique. 30 ml of 0.25% bupivacaine will be injected into this area.

Procedure: Thoracic Paravertebral Block

Patients with a BMI of 25-29.9 kg/m2

ACTIVE COMPARATOR

The needle will be advanced to the paravertebral area with an ultrasound-guided in-plane technique. 30 ml of 0.25% bupivacaine will be injected into this area.

Procedure: Thoracic Paravertebral Block

Patients with a BMI of 30-40 kg/m2

ACTIVE COMPARATOR

The needle will be advanced to the paravertebral area with an ultrasound-guided in-plane technique. 30 ml of 0.25% bupivacaine will be injected into this area.

Procedure: Thoracic Paravertebral Block

Interventions

Thoracic paravertebral block will be applied to the patients under real-time ultrasound guidance.

Patients with a BMI of 18-24.9 kg/m2Patients with a BMI of 25-29.9 kg/m2Patients with a BMI of 30-40 kg/m2

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • to 80 years old
  • ASA physical status I-II-III
  • BMI 18 to 40 kg/m2
  • Elective video-assisted thoracoscopic surgery

You may not qualify if:

  • Patient refusing the procedure
  • Emergency surgery
  • Chronic opioid or analgesic use
  • Patients who will operate under emergency conditions
  • Patients who will not undergo VATS

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Ankara City Hospital

Çankaya, Ankara, 06290, Turkey (Türkiye)

Location

Ankara Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital

Keçiören, Ankara, 06290, Turkey (Türkiye)

Location

Related Publications (1)

  • Zengin EN, Alagoz A, Yigit H, Sazak H, Sekerci S, Zengin M. The effect of body mass index on thoracic paravertebral block analgesia after video-assisted thoracoscopic surgery; a prospective interventional study. BMC Anesthesiol. 2023 Sep 4;23(1):297. doi: 10.1186/s12871-023-02264-0.

MeSH Terms

Conditions

Pain, PostoperativeAcute Pain

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Study Officials

  • Nilgün Zengin, MD

    Ankara City Hospital Bilkent

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal İnvestigator

Study Record Dates

First Submitted

April 25, 2022

First Posted

May 3, 2022

Study Start

April 25, 2022

Primary Completion

May 1, 2023

Study Completion

May 13, 2023

Last Updated

May 16, 2023

Record last verified: 2023-05

Locations